First-Line Bevacizumab for Glioblastoma Not Likely To Be Cost-Effective
the Cancer Therapy Advisor take:
Bevacizumab has only limited effectiveness and is therefore not likely to be cost effective in treating adult patients with newly diagnosed glioblastoma multiforme, a new study published online in the Journal of Clinical Oncology has shown.
For the cost-effectiveness analysis, researchers from St Joseph's Healthcare Hamilton in Ontario, Canada, developed a Markov model to estimate the incremental cost-utility ratio (ICUR) of first-line bevacizumab in newly diagnosed glioblastoma multiforme from a Canadian public payer perspective.
Results of the analysis showed that over a 2-year time horizon, the addition of bevacizumab to radiotherapy and temozolomide resulted in an increase of 0.13 QALYs and $80,000 per patient, corresponding to an ICUR of $607,966/QALY (95% CI: $305,000/QALY to $2,550,000/QALY). The researchers found that at the $100,000/QALY willingness-to-pay threshold, bevacizumab had a 0% chance of being cost-effective.
The researchers note that second-line treatment with bevacizumab is more effective on progression and less expensive than first-line bevacizumab. The findings suggest that further research is unnecessary.
Bevacizumab has limited effectiveness and is therefore not likely to be cost effective in newly diagnosed glioblastoma multiforme.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia